These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 10143664)

  • 21. Disease models.
    Gobburu J
    Clin Adv Hematol Oncol; 2008 Apr; 6(4):241-2. PubMed ID: 18496490
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical trial design issues in schizophrenic research.
    Casey DE
    J Clin Psychiatry; 2001; 62 Suppl 9():17-20; discussion 21-2. PubMed ID: 11379826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interview with Gary L. Yingling, J.D.
    Yingling GL
    Qual Manag Health Care; 1999; 7(3):45-7. PubMed ID: 10537462
    [No Abstract]   [Full Text] [Related]  

  • 24. Ethical implications of pediatric drug research policy initiatives.
    Twomey JG
    IRB; 2000; 22(2):5-10. PubMed ID: 11883466
    [No Abstract]   [Full Text] [Related]  

  • 25. The use of patient-reported outcome measures in the evaluation of medical products for regulatory approval.
    Burke LB; Kennedy DL; Miskala PH; Papadopoulos EJ; Trentacosti AM
    Clin Pharmacol Ther; 2008 Aug; 84(2):281-3. PubMed ID: 18580868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Designing trials for testing prosthetic cardiac valves: a Food and Drug Administration perspective.
    Sapirstein W
    Am Heart J; 2001 May; 141(5):861-3. PubMed ID: 11320379
    [No Abstract]   [Full Text] [Related]  

  • 27. Overhauling clinical trials.
    Scott CT; Baker M
    Nat Biotechnol; 2007 Mar; 25(3):287-92. PubMed ID: 17344876
    [No Abstract]   [Full Text] [Related]  

  • 28. Oncology's first Phase 0 trial.
    Rowan K
    J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
    [No Abstract]   [Full Text] [Related]  

  • 29. Ethics versus legal informed consent--a distinction with little difference.
    Zinman EJ
    J Hist Dent; 2007; 55(3):134-8; discussion 171-85. PubMed ID: 18380247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical predictors of clinical safety: opportunities for improvement.
    Sistare FD; DeGeorge JJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):210-4. PubMed ID: 17507920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tuft's report backs FDA fast-track, but post-marketing concerns loom.
    Vastag B
    Nat Biotechnol; 2006 May; 24(5):478. PubMed ID: 16680113
    [No Abstract]   [Full Text] [Related]  

  • 32. The right to a trial: Should dying patients have access to experimental drugs?
    Groopman J
    New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
    [No Abstract]   [Full Text] [Related]  

  • 33. The FDA's drug review process: ensuring drugs are safe and effective.
    Meadows M
    FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
    [No Abstract]   [Full Text] [Related]  

  • 34. Moment of reckoning.
    Wadman M
    Nature; 2007 Apr; 446(7138):844-5. PubMed ID: 17443154
    [No Abstract]   [Full Text] [Related]  

  • 35. Call for a new approach to the process of clinical trials and drug registration.
    Jones TC
    BMJ; 2001 Apr; 322(7291):920-3. PubMed ID: 11302912
    [No Abstract]   [Full Text] [Related]  

  • 36. Patients, physicians, and clinical trials: the other side of the coins.
    Abramson SB; Flexner C; Snyderman R; Dieterich DT; Korn D; Temple R; Sherwood L; Goldblatt D
    J Investig Med; 1999 Sep; 47(8):343-57. PubMed ID: 10510587
    [No Abstract]   [Full Text] [Related]  

  • 37. Long-acting beta agonists--prescribe with care.
    Crane J
    N Z Med J; 2006 Jul; 119(1237):U2064. PubMed ID: 16862206
    [No Abstract]   [Full Text] [Related]  

  • 38. Identifying quality leads - an important factor in reducing attrition of clinical candidates.
    Chackalamannil S; Desai MC
    Curr Opin Drug Discov Devel; 2007 Jul; 10(4):381-2. PubMed ID: 17659478
    [No Abstract]   [Full Text] [Related]  

  • 39. [Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase].
    Kock M; Thomsen MK
    Ugeskr Laeger; 2003 Apr; 165(16):1649-52. PubMed ID: 12756820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug markers questioned.
    Ledford H
    Nature; 2008 Apr; 452(7187):510-1. PubMed ID: 18385695
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.